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Abstract Since the publication of the JUPITER trial, atten-
tion has been focused on the adverse glycemic effects of statin
therapy. Although the modest increase in the risk of new dia-
betes mellitus is outweighed by the reduction in cardiovascu-
lar events for statins, emerging biochemical and genetic links
between lipid metabolism and glycemic control raise the pros-
pect of a broader diabetogenic effect of lipid-lowering thera-
pies. For the novel and powerful PCSK9-inhibitor class avail-
able evidence does not support a major glycaemic effect with
the results of large scale trials awaited although preliminary
genetic data does suggest a link. In contrast, there is clear
evidence of a diabetogenic effect for the now outdated but
well-studied niacin. For ezetimibe and fibrates, evidence is
scarce but currently broadly unconcerning. For now, the gly-
cemic effects of lipid-lowering therapies should have a limited
influence on clinical decision-making. Further study in this
topical area is needed.
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Introduction
Hypercholesterolaemia is one of the most important modifiable
risk factors for cardiovascular disease. Efficacious for primary
prevention, even in individuals with only modest cardiovascu-
lar risk, statins are some of the most widely used medicines
worldwide. Despite this, a very small proportion of individuals
do not sufficiently respond or are unable to tolerate these drugs.
Although the risks of liver derangement, myositis, and even
rhabdomyolysis, have long been recognised, it was not until
the publication of the 2008 randomised JUPITER trial that
focus turned to modest but significant increases in the new
development of diabetes mellitus [1]. Individuals receiving
maximal doses of rosuvastatin had a 28 % excess rate of dia-
betes (mainly confined to those with preexisting risk factors)
compared to the placebo arm. Subsequent randomised trial
meta-analyses showed a 9–11 % increased risk of diabetes
amongst statin users [23•] with evidence of a higher rates
amongst those on intensive statin therapy [4].
In vitro and population studies have revealed possible
mechanistic explanations. Firstly, ‘off-target’ effects potenti-
ating insulin resistance (inhibition of GLUT4 translocation to
the cell membrane and of adipocyte differentiation) or de-
creased insulin secretion (inhibiting calcium uptake into pan-
creatic beta cells and induction of beta cell apoptosis) have
been proposed [5]. It is suggested that these effects are con-
centrated amongst the lipophilic statins—which may account
for the reduced risk of new-onset diabetes originally seen
amongst users of the hydrophilic pravastatin in the pivotal
West of Scotland Coronary Prevention Study [6]. However,
this line of argument remains speculative and diabetes risk
was clearly elevated in the pravastatin arm of the PROSPER
trial [7]. Secondly, there appear to be downstream ‘on-target’
effects of HMG-CoA reductase inhibition which alter insulin
metabolism and weight and parallel clinical evidence that
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HMG-CoA reductase inhibition leads to minor weight gain
amongst those who take statins [4]. In other words, it appears
that at least part of the diabetogenic potential of statins is
mediated via weight change although the precise mechanisms
are yet to be elucidated but speculatively could include a a
very small effect on exercise capacity sufficient to tip the
balance towards very minor weight gain in some.
Finally, and perhaps most interestingly, there is emerging
evidence of an association between alleles influencing lipid me-
tabolism and the risk of diabetes mellitus. At one extreme, indi-
viduals with familial hypercholesterolaemia have a lower inci-
dence of diabetes mellitus compared to unaffected family mem-
bers—despite early and aggressive treatment with statins [8].
Broader mendelian randomisation studies (the use of genetic
polymorphisms to help dissect causality) including tens of thou-
sands of individuals have suggested an inverse relationship be-
tween single nucleotide polymorphisms (SNPs) predisposing to
elevated LDL cholesterol and the risk of developing diabetes
[9•], with particular alleles for the biological target of statin
therapy implicated [4]. Whilst a number of potential confound-
ing factors prevent firm conclusions (including survivor bias,
pleiotropy, the greater use of statin therapy amongst individuals
with high LDL), the foregoing observations raise the possibility
of an inherent diabetogenic effect of lipid lowering therapies,
especially LDL cholesterol-lowering therapies.
In this review, we summarise the evidence regarding the
glycemic effects of non-statin lipid-lowering therapies, with
results summarised (Table 1).
PCSK9 Inhibitors
The PCSK9 inhibitors (including alirocumab, evolocumab
and bococizumab, although the latter now being with-
drawn) are an emerging drug class of monoclonal antibod-
ies against PCSK9—a binding protein potentiating the
degradation of hepatocyte LDL-R, which can be delivered
subcutaneously at monthly or bimonthly intervals and of-
fer potent reductions in LDL cholesterol (up to 61 %).
Colhoun et al. examined the influence of alirocumab on
transition to diabetes amongst 10 randomised control tri-
als (n = 3448) with a high proportion of prediabetic sub-
jects (39.6 %). They found no clear evidence of increased
development of diabetes compared to placebo (HR 0.64
(0.36–1.14)) or ezetimibe (HR 0.55 (0.22–1.41)) [10••].
Furthermore, there was no significant change in HbA1c
over time. However, the follow-up period was relatively
short (6–18 months), and the total number of new cases of
diabetes was limited (n = 218). Similarly, there was no
significant glycemic effect of monthly evolocumab over
a 52-week period in a randomised comparison with pla-
cebo (n = 901) [11] nor any glycemic effect amongst par-
ticipants in a randomised trial against standard care who
had preexisting dysglycaemia or metabolic syndrome over
52 weeks [12]. In a recent meta-analysis, we did not find
any significant difference in lipid effects of evolocumab
on diabetic patients versus controls [13]. Further work on
the glycaemic effects of evolocumab is currently ongoing.
Table 1 Levels of evidence linking statins and non-statin-based lipid-lowering medications to diabetes risks plus any clinical ramifications
Trial evidence Genetic evidence Clinical ramifications
Statins Meta-analyses of multiple randomised
trials confirm modestly elevated
(9–11 %) diabetes risk and slight
weight gain
HMG-CoA reductase SNPs associated with
a small but discernible increase in the
risk of type 2 diabetes, raised blood
glucose and insulin, and higher body
weight
Modest diabetes risks do not alter statin
prescription recommendations to those
with established disease or at elevated
risk. However, the risk should be
mentioned to patients to further
incentivise lifestyle changes. HbA1c or
fasting glucose should be checked prior
to statin commencement.
PCSK9 inhibitors Short-term (6–18 months) trial with
alirocumab does not support a
measurable effect on diabetes risk
Longer term data needed, as well as data
for other PCSK9 inhibitors
Emerging genetic evidence of slight
increased (19%: 95% CI 2 to 38%)
diabetes risk for genetically determined
1 mmol/l LDL-c reduction .
None as yet
Ezetimibe Non-significant 9 % increased risk in
IMPROVE-IT reported as
abstract—yet to be fully published
Recent genetic evidence for a significant
diabetes risk (Odds ratio 2.42; 95% CI
1.70 to 3.43) associated with alleles in or
near NPC1L1, the molecular target for
Ezetimibe.
None as yet
Niacin 34 % increased risk of new diabetes
associated with the use of niacin in
meta-analysis of trial data
No published data None since niacin is no longer
recommended due to its lack of clinical
outcome benefit.
Fibrates Prior limited evidence suggesting
bezafibrate may lower diabetes
risk but no clear evidence of an effect
of fenofibrate in the FIELD trial
Mixed genetic data on the association of
PPAR-alpha SNPs with diabetes: more
studies needed
None
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Although the data for PCSK9 inhibitors is thus far
reassuring, a more subtle effect cannot be excluded and
it is notable that widespread acceptance of the link be-
tween statins and diabetes came only after large scale
meta-analysis including thousands of new cases of diabe-
tes. Furthermore, most trials have examined the addition
of PCSK9 inhibitors to statins which may partially mask a
diabetogenic effect if mechanisms are shared between
classes. Further work in this area is proceeding rapidly
especially regarding SNPs related to PCSK9 function
and glycaemic control as well as to weight changes.
Such work requires the integration of results from multi-
ple large studies to yield sufficient power and is now
readily achievable in an era of both major genetic studies
and distributed information technology. Indeed, a recent
relevant study exploiting genetic data has examined this
issue and reported genetic variants in PCSK9 were
associated with a 19 % (95 % CI 2 to 38 %) higher risk
for diabetes per mmol/l lower LDL-c levels [14••]. This is
the first large genetic study linking PCSK9 snps to diabe-
tes risk and reports a significant higher risk, albeit mod-
estly so, but with stronger associations with diabetes for
genes encoding the molecular targets for ezetimibe.
Nevertheless, the results of ongoing cardiovascular end-
point trials are needed to determine the true effect of short
term PCSK9 inhibition on diabetes risks. Fortunately, we
will not have to wait too long for these to report and all
have pre-specified assessment of diabetes risk and HbA1c
from the outset.
One final comment deserves mention. Since these drugs
are currently being targeted to those at very high risk of car-
diovascular events—i.e. patients with either familial hyper-
cholesterolaemia or preexisting cardiovascular disease with
uncontrolled LDL cholesterol despite maximally tolerated
statin and/or ezetimibe therapy—it is unlikely that a modest
diabetogenic effect would alter treatment decisions [15•].
Niacin
The B vitamin niacin initially showed promise, with a
reduction in 17 % reduction in MI seen in results from
the Coronary Drug Project [16], but despite beneficial
effects on serum LDL no clear benefit in cardiovascular
events or mortality was seen in addition to statin thera-
py [17, 18]. As well as the well-recognised flushing
effects of niacin, one notable side effect is a worsening
of glycemic control. Although early work concluded this
effect was modest and unlikely to lead to the onset of
diabetes [19], post hoc analysis, new trials and a well
conducted meta-analysis of both published and unpub-
lished work are concordant in suggesting a significant
effect. Over a 5-year follow-up, in the Coronary Drug
Project’s randomised comparison of niacin to placebo,
patients with impaired fasting glucose tolerance at base-
line progressed to diabetes at a rate of 19.8 % on niacin
versus 15.2 % on placebo (HR 1.34 (1.00–1.80)) with a
similar (although non-significant) relative risk increase
amongst those with normal glucose tolerance (HR 1.41
(0.97, 2.05)) [20]. In the HPS2-THRIVE comparison of
the addition of niacin or placebo to those already on
statins there was a 55 % increase in serious disturbances
in glycemic control (for which many patients were
hospitalised), affecting 11.2 % of diabetics assigned to
niacin [7]. Furthermore, there was a 30 % increase in
the risk of new-onset diabetes in the treatment group.
Goldie et al. performed a rigorous meta-analysis on the
effect of niacin on the risk of new-onset diabetes [21•].
Overall, they found a 34 % increased risk of new dia-
betes associated with the use of niacin (although this
may be a slight overestimate as trials with no new cases
of diabetes were excluded). Niacin is no longer in wide-
spread clinical use but these results do add to concerns
of an implicit diabetogenic effect of lipid-lowering
therapies.
Ezetimibe
Ezetimibe inhibits enterocyte absorption and increases hepa-
tocyte uptake of cholesterol and currently is the mainstay of
therapy in individuals who do not tolerate statins or require
further LDL cholesterol reductions. Added to statin therapy, it
offers both a 15 % absolute reduction in LDL cholesterol [22]
and a modest reduction in cardiovascular events over a 7-year
post-acute coronary syndrome ((HR 0.94 (0.89, 0.99)) [23],
but data regarding its glycemic effects are rather limited. Saito
et al. randomised diabetics to ezetimibe or placebo and did not
find any significant effect on glycemic control (assessed by
either HbA1c or fasting plasma glucose) or exacerbations of
diabetes over a short follow-up period of 24 weeks [24].
However, 9 % of diabetics in the ezetimibe group had their
drug regime altered due to hyperglycaemia versus 4 % of the
placebo group. Although the trial was well conducted, its very
limited sample size (n = 152), single nationality population
(Japanese) and exclusion of those with poor diabetic control,
preexisting cardiovascular disease or concurrent statin use
means wider interpretation of its results is fraught. In the
IMPROVE-IT randomised comparison of additional
ezetimibe or placebo for subjects on statins with recent acute
coronary syndrome a preliminary report, not yet peer-
reviewed, suggests ezetimibe resulted in a small, non-
statistically significant, increase in the relative risk of new-
onset diabetes (9 % per 1 mmol/L reduction in LDL choles-
terol) [25•]. These clinical data should be contrasted with re-
cent genetic data [14••] which suggests a much larger effect on
diabetes risk of lifelong inhibition of the genes encoding the
molecular targets of ezetimibe: a 2.42 (95 % CI 1.70 to 3.43)
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odds ratio per mmol/l lower LDL-c. Therefore, longer term
data on diabetes risks with ezetimibe treatment are needed to
rule out a diabetes risk.
Fibrates
Fibrates interact with peroxisome proliferator-activated recep-
tors to reduce plasma LDL cholesterol and triglycerides.
Although they reduce the rate of cardiovascular events, they
do not affect all-cause mortality or rates of cardiovascular death
[26]. Overall there is very limited data on the interaction be-
tween fibrates and glycemic control. The FIELD study
randomised diabetic subjects not on any statin therapy at base-
line (n = 9795) to either fenofibrate or placebo. Over 6 years, the
change in HbA1c was negligible regardless of randomisation
but formal statistical testing was not reported [27]. Lee et al.
examined the effects of fibrates on the rate of new-onset diabetes
amongst Taiwanese patients aged 55–59 with dyslipidaemia
(n = 3815) over a 5-year period [28]. Although the overall rate
of new-onset diabetes was unconcerning (3.8 %), the number of
new diabetes cases was limited (n = 145) and the lack of a
comparison group means no firm conclusions can be drawn.
Tennabaum et al. found a reduced rate of diabetes over a 6-
year follow-up amongst subjects with impaired fasting glucose
and known coronary artery disease assigned to benzafibrate
rather than placebo [29]. There are also mixed data on the asso-
ciation of PPAR-alpha SNPs and diabetes risk, and thus, overall,
no clear conclusions can yet be drawn [30]. Newer classes of
fibrate drugs are currently being tested with respect to cardio-
vascular outcome risks and it is likely that such studies will also
include measures of glycaemia as pre-specified outcomes.
Conclusions
It is striking that both genetic studies and large scale meta-
analysis for statins and niacin (the two lipid-lowering thera-
pies for which there is a reasonable body of data) point to-
wards an inverse link between LDL cholesterol and glycemic
control, although niacin also influences HDL-cholesterol
levels which may have separate links to diabetes. However,
it is not yet clear that all lipid-lowering therapies are implicitly
diabetogenic, or that all statins are equally diabetogenic [31]).
There are a number of gaps in the literature. Further
studies delineating the mechanisms by which statins
cause diabetes are clearly needed. Both ezetimibe and
PCSK9 inhibitors lack sufficient clinical trial data to ex-
clude a diabetogenic effect, although, as noted, large
scale trials of PCSK9 inhibitors are underway, and will
also examine diabetes outcomes, important given emerg-
ing evidence of a link between PCSK9 genetic variants
and diabetes risk.
For PCSK9 inhibitors, any diabetogenic effect would have
to be very significant to further limit their use beyond individ-
uals at high risk of cardiovascular events without other proven
options. For statins, the benefits clearly outweigh the risks,
even for primary prevention. Potential diabetogenic effects
can be easily monitored, managed and mitigated by lifestyle
changes. Indeed, a positive consequence of this area is that
more patients at risk of, or with existing cardiovascular dis-
ease, are screened for diabetes, receive preventative advice
and have earlier diagnosis and treatment.
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